MARKET

ATAI

ATAI

Atai Life Sciences B.V.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.640
-0.040
-1.09%
After Hours: 3.670 +0.03 +0.82% 19:44 06/30 EDT
OPEN
3.610
PREV CLOSE
3.680
HIGH
3.680
LOW
3.500
VOLUME
431.26K
TURNOVER
0
52 WEEK HIGH
20.45
52 WEEK LOW
2.950
MARKET CAP
585.07M
P/E (TTM)
-2.5907
1D
5D
1M
3M
1Y
5Y
atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO
Kures Therapeutics, an atai Life Sciences (NASDAQ:ATAI) <a href=...
Seekingalpha · 23h ago
atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
Dr. Chad Beyer will join as CEO on July 1, 2022NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Kures Therapeutics, Inc (“Kures”), an atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) company focused on developing treatment options to better manage addictions, de...
GlobeNewswire · 1d ago
Atai Life Sciences Unit Kures Names New CEO
MT Newswires · 1d ago
10 Psychedelics CEOs To Pay Attention To In 2022
By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public.
Benzinga · 2d ago
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.12% at $0.82
Benzinga · 3d ago
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.63% at $0.71
Benzinga · 06/23 22:22
Psychedelic Stock Gainers And Losers From June 22, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 4.17% at $3.50
Benzinga · 06/22 20:34
US Senate Moves Forward On Gun Reform: 3 Stocks That Could Benefit As A Result
Tuesday night, the U.S. Senate finally cleared a procedural vote to move forward with gun control legislation. The action comes after weeks of negotiations.
Benzinga · 06/22 12:27
More
No Data
Learn about the latest financial forecast of ATAI. Analyze the recent business situations of Atai Life Sciences B.V. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

23.08%Strong Buy
69.23%Buy
7.69%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATAI stock price target is 25.92 with a high estimate of 50.00 and a low estimate of 8.00.
High50.00
Average25.92
Low8.00
Current 3.640
EPS
Actual
Estimate
-0.50-0.37-0.25-0.12
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 86
Institutional Holdings: 18.48M
% Owned: 11.49%
Shares Outstanding: 160.73M
TypeInstitutionsShares
Increased
24
1.94M
New
23
2.49M
Decreased
23
1.60M
Sold Out
22
1.15M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About ATAI
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The company is aiming to transform the treatment of mental health disorders.

Webull offers kinds of ATAI Life Sciences NV stock information, including NASDAQ:ATAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATAI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATAI stock methods without spending real money on the virtual paper trading platform.